Recent publications

• Importance of Residency Training for the Provision of Comprehensive Clinical Pharmacy Services May 9, 2026
  In 2006, the American College of Clinical Pharmacy (ACCP) issued a position statement recommending residency training as a prerequisite for entering direct patient care activities. Additional recommendations in 2013 added residency training as a prerequisite for providing direct patient care. Over the subsequent 12 years, patient-level services by pharmacists expanded, and the frequency of team-based […]
  Keith M Olsen
• Impact of New York Heart Association classification on transthyretin stabilizer efficacy in transthyretin amyloid cardiomyopathy: A meta-analysis May 5, 2026
  CONCLUSION: Transthyretin stabilizers showed beneficial effects on all outcomes when assessed in patients with NYHA class I/II disease, but no benefit was found in the NYHA class III subgroup. These findings reinforce the importance of early-stage ATTR-CM diagnosis and treatment.
  Huiqiao Fan
• Duration of Antifungal Therapy in Disseminated Coccidioidomycosis Patients: A Real-World Treatment Utilization Study April 27, 2026
  Background: Disseminated coccidioidomycosis (DCM) often requires prolonged antifungal therapy (AFT). Real-world data on AFT duration in DCM are limited. We evaluated time to AFT discontinuation among patients with DCM in the United States clinical practice. Methods: This retrospective, longitudinal study used STATinMED data (2016-2024). Patients had ≥1 International Classification of Diseases, Tenth Revision (ICD-10) code […]
  Craig I Coleman
• Periodontal Disease and Risk of Heart Failure: A Systematic Review and Meta-Analysis April 24, 2026
  Periodontal disease (PD) has been hypothesized to influence the risk of heart failure (HF), but the evidence remains inconclusive. We conducted a systematic review to evaluate the association between PD and HF. PubMed, Embase, Scopus, and Web of Science were searched from inception to October 2024. We selected cohort studies assessing the association between PD […]
  German Valenzuela-Rodríguez
• Comment on "Adopting Race-Free Estimated Glomerular Filtration Rate for Unifying Medication-Related Decision-Making: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy" April 20, 2026
  No abstract
  Nicole L Metzger
• The Impact of a Pharmacist-Driven, Interprofessional Lipid Optimization Workflow in a Transitions of Care (LOW-TOC) Pilot Program April 20, 2026
  CONCLUSIONS: The implementation of the LOW-TOC approach to CV team-based lipid management was associated with significantly increased optimizations compared with the standard process typically utilized in many health systems. These findings support the utility of pharmacists leading the CV team in optimizing lipid management using a population health model in TOC settings.
  Jillian Searle
• Identification and Characterization of Mitragynine or 7-Hydroxymitraynine Oral Dosage Form Products That Appeal to Children April 15, 2026
  CONCLUSIONS: Mitragynine and 7-hydroxymitragynine are present in many products that could cause small children and teens to be exposed.
  C Michael White
• Contemporary Immunosuppression in Simultaneous Heart-Kidney Transplantation: A United Network for Organ-Sharing Database Analysis April 8, 2026
  CONCLUSION: Contemporary SHKT recipients experience similar 1-year outcomes across induction strategies. Basiliximab may be sufficient for standard-risk SHKT recipients.
  Xinyi Huang
• 10th anniversary: The development, implementation, and evaluation of a novel peer-assisted learning (PAL) program April 3, 2026
  CONCLUSION: The outcomes of this report suggest that including various PAL modalities in the didactic pharmacy curriculum can increase student confidence in learning and perceived performance on assessments. The PAL program presented appears feasible, effective, and sustainable.
  Nathaniel M Rickles
• Association of the C-reactive protein-triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study April 2, 2026
  No abstract
  Ramin Assempoor
• Efficacy of Oral Arginine as Treatment to Improve Height in Prepubertal Children With Idiopathic Short Stature: A Systematic Review and Meta-Analysis March 30, 2026
  CONCLUSION: Oral arginine administered for 12 months may not affect growth. Well-designed RCTs are required.
  Manuel André Virú-Loza
• It's time to improve antithrombotic therapy! A global perspective for antithrombotic stewardship March 19, 2026
  Antithrombotic drugs are a class of medications with the highest rates of serious and life-threatening adverse events, many of which are preventable with proper knowledge and systems of management. Antithrombotic stewardship is a care model shown to improve outcomes and is gaining traction throughout the world. Stewardship implies a comprehensive system of care employing coordinated, […]
  W Ageno
• Incidence and outcomes of major bleeding among first-time oral factor Xa inhibitor users: multinational observational cohort studies March 18, 2026
  CONCLUSION: Results of this large-scale study indicate that the incidence of major bleeding remains elevated during the first 3 years after initiating FXai treatment and that these bleeding events seemed to be associated with significant mortality.
  Alexander T Cohen
• Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials March 14, 2026
  Background/Objectives: There are conflicting results on the effects of ferric derisomaltose (FDM) vs. iron sucrose (IS) for treatment of iron deficiency anemia (IDA). We systematically assessed the efficacy and safety of these treatments. Methods: We searched Ovid MEDLINE, Web of Science, Pubmed, and Cochrane Central for randomized controlled trials (RCTs) comparing the efficacy and/or safety […]
  Lokman H Tanriverdi
• Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States March 11, 2026
  CONCLUSIONS: Finerenone was primarily prescribed as a pillar of therapy that is used in combination with complementary medications in patients with T2D and CKD, aligning with clinical guidelines and regulatory labeling.
  Csaba P Kovesdy
• Bury my axe in wounded knee: A case of native knee septic arthritis caused by multidrug resistant <em>Lomentospora</em> <em>prolificans</em> March 9, 2026
  A 39-year-old male presenting with swelling and pain in the left knee after traumatic injury was diagnosed with rapidly progressive septic arthritis of the knee due to pan-resistant Lomentospora prolificans. While L. prolificans is an environmental mold, it infrequently causes infection in immunocompetent patients. These hosts most commonly suffer soft tissue or osteoarticular infections following […]
  Weston Carpenter
• Using the ACCP Toolkit to Evolve the PharmD Curriculum March 1, 2026
  CONCLUSION: Using the ACCP Toolkit in the curricular assessment process was effective in identifying areas of curricular overload and informing areas for improvement in a subsequent curricular revision, leading to adjustment of credits and time spent on pharmacotherapy topics within courses.
  Jennifer Luciano
• Short-Term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States February 24, 2026
  CONCLUSIONS: Both LVAD and HT had comparable burdens on resources and short-term rehospitalization risk.
  Balaphanidhar Mogga
• Efficacy and harms of polypills for cardiovascular disease prevention: A systematic review and meta-analysis of randomized controlled trials February 20, 2026
  CONCLUSIONS: In primary and secondary prevention settings, polypills had moderate reductions of CV outcomes, small effects on CV risk factors, and small increases of AEs.
  Brian M Portela
• Risk scoring for the primary prevention of cardiovascular disease February 17, 2026
  This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of evaluating and providing cardiovascular disease (CVD) risk scores in adults without prevalent CVD on cardiovascular outcomes, risk factor levels, preventive medication prescribing, and health behaviours.
  Adrian V Hernandez